




RealRate

PHARMACEUTICAL 2022

BioXcel Therapeutics Inc.
Rank 270 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

BioXcel Therapeutics Inc.
Rank 270 of 475



The relative strengths and weaknesses of BioXcel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioXcel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 203% points. The greatest weakness of BioXcel Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is -148%, being 128% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	236,812
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,667
Liabilities, Non-Current	1,105
Other Assets	1,333
Other Compr. Net Income	0
Other Expenses	40
Other Liabilities	0
Other Net Income	44
Property and Equipment	1,294
Research and Development	52,708
Revenues	0
Selling, General and Administrative Expense	54,227

Output Variable	Value in 1000 USD
Assets	239,439
Liabilities	17,772
Expenses	106,975
Stockholders Equity	221,667
Net Income	-106,931
Comprehensive Net Income	-106,931
Economic Capital Ratio	-148%

